NMS-P937
Onvansertib, also know as NMS-P937, PCM-075 and NMS1286937, is a n orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor NMS-1286937 selectively inhibits PLK1, inducing selective G2/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G1 and G2 stages without apoptosis in normal cells. PLK1 inhibition may result in the inhibition of proliferation in PLK1-overexpressing tumor cells. PLK1 is a serine/threonine protein kinase crucial in the regulation of mitosis.
Product Specifications
CAS Number
1034616-18-6
Product Name Alternative
PCM-075 | PCM 075 | NMS1286937
Field of Research
Neuroscience
Purity
>98% (HPLC)
Solubility
DMSO : 21 mg/mL. 39.44 mM
Smiles
CN1CCN (CC1) c1cc (c (cc1) OC (F) (F) F) Nc1ncc2CCc3c (c2n1) n (nc3C (=O) N) CCO
Molecular Formula
C24H27F3N8O3
Molecular Weight
532.52
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
1- (2-hydroxyethyl) -8- ((5- (4-methylpiperazin-1-yl) -2- (trifluoromethoxy) phenyl) amino) -4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Importin 9 Recombinant Antibody, AbBy Fluor™ 405 Conjugated
